MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$666,904
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds received from the febru...
    • Change in fair market value of d...
    • Proceeds from issuance of debt
    • Others
Negative Cash Flow Breakdown
    • Net loss from continuing operati...
    • Accrued liabilities and other pa...
    • Disbursements for the february 2...
    • Others
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
(income) loss from equity method investment
-
0
0
392,677
Income Loss From Equity Method Investments
-
392,677
-
-
Income from equity method investment - lab services mso
-
0
-
-
AIGenerated Polishing
-
94,553
-
-
Corporate Other
-
7,889,483
-
-
Other operating expenses
-
7,984,036
-
-
Interest Expense Nonoperating
-
1,456,694
-
-
Interest expense
-
1,456,694
-
-
Gains Losses On Extinguishment Of Debt
-
-9,076,587
-
-
Loss on extinguishment of debt
-
-9,076,587
-
-
Other income (expense)
-
605,767
-
-
Loss on extinguishment of debt
-
0
0
9,076,587
Net loss from continuing operations
-4,376,680
-17,518,873
-
-
Credit loss provision
-
-
-
1,650,000
Depreciation and amortization of intangible assets
563,158
-38,652
44,335
88,760
Net loss
-
-
-254,268
-15,940,709
Change in straight-line rent receivable
-
-
12,621
-58,586
Amortization of operating lease right-of-use asset
16,398
15,633
15,127
33,628
Rent receivable
-
-
-1,747
6,381
Stock-based compensation and service expense
319,819
393,484
661,280
761,698
Security deposit
-
79
80
17,332
Amortization of debt issuance costs and debt discount
189,417
-18,898
31,339
1,123,971
Distribution of earnings from equity method investment
-
0
0
-
Deferred leasing costs
-
-
23,732
-
Change in fair market value of derivative liability
1,276,889
-66,267
-25,130
-446,816
Deferred leasing costs
-
-
-
15,877
Impairment of laboratory equipment
-
0
-
-
Prepaid expense and other assets
37,854
-162,331
-70,288
254,918
Distribution of earnings from equity method investment
-
-
-
0
Debt modification charge
-
0
-
-
Accrued liabilities and other payables
-796,128
764,819
-235,640
1,220,868
Accrued liabilities and other payables - related parties
-
0
0
0
Operating lease obligation
-15,398
-15,633
-15,127
-33,628
Net cash used in operating activities
-
-
-1,360,735
-3,027,822
Net cash used in operating activities from continuing operations
-2,860,379
-4,580,620
-
-
Improvement of commercial real estate
-
-
35,865
-
Cash acquired on acquisition
-
14,026
-
-
Proceeds from sale of equity method investment
280,500
280,500
693,500
95,000
Payment for equity interest purchase
-
0
0
0
Net cash provided by investing activities from continuing operations
-472,135
-
657,635
95,000
Net cash provided by (used in) investing activities from continuing operations
-
1,083,026
-
-
Proceeds from issuance of convertible debt
-
0
200,000
-
Advance from pending sale of noncontrolling interest in subsidiary
-
0
-100,000
149,972
Proceeds from issuance of convertible preferred stock
-
0
300,000
0
Payments of convertible preferred stock issuance costs
-
0
10,000
-
Proceeds from issuance of bridge loan
-
300,000
-
-
Proceeds from issuance of common stock and warrants
-
0
475,500
-
Payments of offering costs
-
12,051
30,265
22,336
Proceeds from stock subscription liability
-
0
150,000
-
Proceeds from issuance of convertible debt and warrants
-
0
-
-
Payments of convertible debt issuance costs
-
0
0
0
Repayments of bridge loan
250,000
0
-
-
Repayments of convertible debt
200,000
0
0
0
Proceeds from issuance of debt
1,164,000
-
0
-
Payments of debt issuance costs
34,000
-
-
-
Proceeds from equity offering
-
0
0
-
Proceeds received from the february 2026 private offering
3,249,412
-
-
-
Proceeds from stock subscription liability
-
-
-
150,000
Disbursements for equity offering costs
-
0
0
-
Disbursements for the february 2026 private offering costs
492,600
-
-
-
Net cash provided by financing activities from continuing operations
3,436,812
287,949
835,235
277,636
Net cash used in operating activities from discontinued operations
-231,956
-407,434
-
-
Net cash used in investing activities from discontinued operations
-
-35,865
-
-
Net cash flows used in discontinued operations
-231,956
-443,299
-
-
Effect of exchange rate on cash - continuing operations
41,927
-9,691
264
409
Net increase (decrease) in cash
666,904
-26,713
132,399
-2,654,777
Cash - beginning of period
109,091
333,931
2,856,309
-
Cash - end of period
775,995
109,091
333,931
-
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds received fromthe february 2026...$3,249,412 Proceeds from issuance ofdebt$1,164,000 Net cash provided byfinancing activities from...$3,436,812 something is missing$752,635 Effect of exchange rateon cash -...$41,927 Canceled cashflow$976,600 Net increase(decrease) in cash$666,904 Canceled cashflow$3,564,470 Disbursements for the february2026 private...$492,600 Repayments of bridge loan$250,000 Repayments of convertibledebt$200,000 Payments of debt issuancecosts$34,000 Change in fair marketvalue of derivative...$1,276,889 Depreciation andamortization of intangible...$563,158 Stock-based compensationand service expense$319,819 Amortization of debt issuancecosts and debt...$189,417 Amortization of operatinglease right-of-use...$16,398 Proceeds from sale ofequity method...$280,500 Net cash used inoperating activities from...-$2,860,379 Net cash provided byinvesting activities from...-$472,135 Net cash flows usedin discontinued...-$231,956 Canceled cashflow$2,365,681 Canceled cashflow$280,500 Net loss fromcontinuing operations-$4,376,680 something is missing-$752,635 Net cash used inoperating activities from...-$231,956 Accrued liabilities andother payables-$796,128 Prepaid expense andother assets$37,854 Operating leaseobligation-$15,398

Avalon GloboCare Corp. (ALBT)

Avalon GloboCare Corp. (ALBT)